Insight Molecular Diagnostics Inc. (IMDX) Gross margin 2020–2025
Insight Molecular Diagnostics Inc. (IMDX) gross margin by fiscal year — reported gross profit divided by reported revenue.
56.7%FY2025 · since FY2020: -52.5% → 56.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 56.7% | +17.3 pp |
| FY2024 | 39.3% | +11.9 pp |
| FY2023 | 27.5% | +29.4 pp |
| FY2022 | -1.9% | -66.5 pp |
| FY2021 | 64.6% | +117.2 pp |
| FY2020 | -52.5% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More IMDX financial trends
IMDX RevenueIMDX Net incomeIMDX Net marginIMDX Gross profitIMDX Operating incomeIMDX Operating marginIMDX Operating cash flowIMDX Free cash flowIMDX Capital expendituresIMDX Return on equityIMDX Stock buybacksIMDX Dividends paidIMDX Total assetsIMDX Total liabilitiesIMDX Shareholders’ equityIMDX overview →